Vericel

#4216

Rank

$2.12B

Marketcap

United States

Country

Leadership team

Mr. Dominick C. Colangelo Esq. (CEO, Pres & Director)

Mr. Michael Halpin (Chief Operating Officer)

Mr. Joseph Anthony Mara Jr. (CFO & Treasurer)

Products/ Services

Biotechnology, Life Science, Therapeutics

Number of Employees

100 - 500

Headquarters

Ann Arbor, Michigan, United States

Established

1989

Company Registration

SEC CIK number: 0000887359

Revenue

100M - 500M

Traded as

VCEL

Social Media

URL

https://vcel.com

Overview

Location

Recognition and Award

References

Summary

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns. Its preapproval stage product is NexoBrid, a registration-stage biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.

History

Vericel was founded in 2003. Initially, they focused on the development and delivery of advanced autologous cell therapies, primarily for the treatment of damaged joint cartilage. Since then, they have expanded their focus and product portfolio to include tissue repair in multiple indications including skin and burn care, muscle and tendon repair, and other medical conditions. Since their start, Vericel has helped pioneer the way for scientifically-validated and cost-effective cell therapy treatments.

Mission

To develop innovative and clinically effective cellular therapies to improve patient outcomes and reduce healthcare system costs.

Vision

To create a future where cellular therapy is a safe, effective, and affordable treatment option for any patient suffering from a tissue repair-related condition.

Key Team

Mr. Jonathan Siegal (Principal Accounting Officer, VP & Corp. Controller)

Mr. Sean C. Flynn (Sr. VP, Gen. Counsel & Sec.)

Mr. Eric Burns (Exec. Director of Financial Planning and Analysis & Investor Relations)

Dr. Jonathan M. Hopper FRCSEd., M.B. Ch.B. (Chief Medical Officer)

Ms. Heidi Hassen (VP of HR)

Mr. Roland DeAngelis (Sr. VP of Commercial Operations)

Mr. Patrick J. Fowler (Sr. VP of Corp. Devel. & Strategy)

Recognition and Awards

Vericel is a two-time recipient of the FierceBiotech Fierce 15 award, which recognizes those companies that have shown the most potential to make an impact on the industry over the preceding year.